Folate / Folic Acid
Vitamin B9 (pteroylmonoglutamic acid)
The pregnancy-essential B vitamin that prevents neural tube defects and lowers homocysteine.
Strong evidence
🍊Vitamin
Evidence tier
Strong
Research weight
Citations
14 verified / 14
Classification
Vitamin
❝
What the evidence says. Graded strong for preventing neural-tube defects in pregnancy (an 'A'-grade USPSTF recommendation) and for correcting folate-deficiency anaemia. It lowers homocysteine by ~25% but, despite that, large trials show it does not cut heart attacks in most people. (Strong evidence: Multiple high-quality RCTs / meta-analyses with consistent effects.)
What is Folate / Folic Acid?
Folate / Folic Acid (Vitamin B9 (pteroylmonoglutamic acid)) is a vitamin used for periconceptional supplementation substantially reduces the risk of neural tube defects (spina bifida, anencephaly) in offspring — the best-established benefit. NutriDex grades the human evidence as Strong. Folate (vitamin B9) is an essential water-soluble vitamin required for one-carbon metabolism, DNA synthesis, and methylation; "folic acid" is the stable synthetic form used in supplements and food fortification. Its strongest, guideline-endorsed benefit is the prevention of neural tube defects: randomized and observational evidence consistently shows that taking folic acid before and in early pregnancy markedly lowers the risk of spina bifida and anencephaly, and the USPSTF (2023) gives an "A" recommendation that all who could become pregnant take 400-800 mcg daily. Folic acid also reliably lowers blood homocysteine by about 25%, though large cardiovascular outcome trials have not translated this into fewer heart attacks or strokes in most populations. It treats folate-deficiency anemia and is broadly safe within recommended doses. The main cautions are that high folic acid intake can correct the anemia of vitamin B12 deficiency while allowing neurological damage to progress undetected, and a long-debated (but not confirmed in pooled RCT data) concern about promotion of pre-existing colorectal lesions at high doses.
Purported Benefits
✓Periconceptional supplementation substantially reduces the risk of neural tube defects (spina bifida, anencephaly) in offspring — the best-established benefit
✓Lowers blood homocysteine by roughly 25% (~3 µmol/L), with the largest effect in people who start with high homocysteine or low folate
✓Corrects and prevents folate-deficiency (megaloblastic) anemia
✓Adequate intake supports normal DNA synthesis, cell division, and red-blood-cell formation
✓Note: despite lowering homocysteine, large trials show folic acid does NOT meaningfully reduce heart attacks or overall cardiovascular mortality in most populations
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Neural tube defect preventionPericonceptional folic acid cuts NTD risk ~70% (Cochrane RR ~0.31); USPSTF Grade A. Best-established benefit. | Strong | ↑ benefit · large | 4 |
| Homocysteine loweringLowers plasma homocysteine ~25% (~3 umol/L), near-maximal at >=0.8 mg/day; a biomarker, not a clinical endpoint. | Strong | ↑ benefit · moderate | 1 |
| Stroke prevention~10% stroke risk reduction overall, concentrated in unfortified regions and primary prevention; no benefit where grain is fortified. | Moderate | ↑ benefit · small | 2 |
| Folate-deficiency (megaloblastic) anemiaCorrects and prevents folate-deficiency anemia; mechanistically established, though entry leans on guideline/mechanism rather than RCTs. | Strong | ↑ benefit · large | 1 |
| Cardiovascular events / mortalityDespite lowering homocysteine, large trials show no meaningful reduction in heart attacks or CV mortality in most populations. | Moderate | — no effect · negligible | 1 |
| Cancer incidence (safety)IPD meta-analysis of ~50,000 found no significant effect on overall or colorectal cancer; reassuring on the long-debated harm. | Moderate | — no effect · negligible | 1 |
| Offspring neurodevelopment (ASD/ADHD)Umbrella review links maternal folic acid to lower ASD/ADHD odds, but included evidence is mostly low-quality and observational. | Preliminary | ↑ benefit · moderate | 1 |
Dosing & Compounds
Typical Dose
400-800 mcg/day for anyone who could become pregnant (start >=1 month before conception); 4-5 mg/day if prior NTD-affected pregnancy or high risk; general adult RDA ~400 mcg DFE/day. Tolerable upper intake for synthetic folic acid: 1,000 mcg/day.
Active Compounds
Safety & Cautions
Folic acid is generally very safe at recommended doses; the tolerable upper intake level for synthetic folic acid is 1,000 mcg/day in adults (higher therapeutic doses are used under medical supervision, e.g., 4-5 mg for high-risk pregnancy). KEY RISK: high folic acid intake can mask the megaloblastic anemia of vitamin B12 deficiency while allowing irreversible neurological damage to progress — important for older adults, vegans, and people with malabsorption, who should have B12 status checked. A long-debated cancer-promotion signal (potentially accelerating pre-existing colorectal adenomas at high doses) has NOT been confirmed in pooled RCT data but warrants avoiding chronic megadoses without indication. Interactions: methotrexate, anti-epileptics (phenytoin, valproate, carbamazepine), sulfasalazine, trimethoprim, and pyrimethamine are folate antagonists — dosing and timing should be coordinated with a clinician (folate can reduce some chemotherapy/antifolate efficacy). People taking these drugs, those with untreated B12 deficiency, or with a history of folate-sensitive cancers should consult a clinician before supplementing. Rare hypersensitivity reactions can occur. Educational only — always check with your doctor or pharmacist before combining Folate / Folic Acid with any medicine.
Key Studies ★ 14 studies
Systematic review
eClinicalMedicine 2023 (Fortification)
✓ Full text
Across 193 countries, mean NTD prevalence per 10,000 was 4.19 with mandatory folic acid fortification vs 7.61 voluntary and 9.66 no fortification; mean plasma folate was 36 vs 21 vs 17 nmol/L respectively.
Meta-analysis
Moges 2024
✓ Source
Systematic review and meta-analysis found folic acid intake substantially reduced the prevalence of congenital anomalies in offspring (OR 0.23; 95% CI 0.16-0.32).
Systematic review
Umbrella review 2025 (Nutrients)
✓ Full text
Umbrella review of systematic reviews/meta-analyses found maternal folic acid supplementation associated with lower offspring risk of autism spectrum disorder (OR 0.66; 95% CI 0.55-0.79), ADHD (OR 0.86; 95% CI 0.78-0.95), and behavioral problems (OR 0.75; 95% CI 0.63-0.91), though included evidence was of mostly low quality.
Meta-analysis
Zhang 2024
✓ PubMed
Largest meta-analysis to date (21 RCTs, 115,559 participants): folic acid supplementation reduced stroke risk by 10% overall (RR 0.90, 95% CI 0.83-0.98); benefit concentrated in regions without grain fortification (RR 0.83, 95% CI 0.75-0.93) and in primary prevention (no prior stroke/MI: RR 0.77, 95% CI 0.68-0.86), with no benefit where grain is fortified (RR 1.04).
Guideline
USPSTF (Davidson) 2023 Reaffirmation Recommendation Statement
✓ PubMed
Grade A recommendation: all persons planning or capable of pregnancy should take a daily supplement of 0.4-0.8 mg (400-800 ug) folic acid, starting at least 1 month before conception through the first 2-3 months of pregnancy; high certainty of substantial net benefit for preventing neural tube defects (NTDs).
Meta-analysis
Vollset 2013
✓ PubMed
Individual-participant meta-analysis of 13 RCTs (49,621 participants) at supplemental doses far above fortification: folic acid quadrupled plasma folate but had no significant effect on overall cancer incidence (RR 1.06, 95% CI 0.99-1.13, p=0.10) and no significant effect on colorectal, prostate, lung, or breast cancer; key safety evidence supporting fortification.
Cochrane systematic review
31 trials / ~7,700 women (Cochrane)
✓ Full text
Periconceptional folate supplementation substantially reduced first-occurrence and recurrence of neural tube defects (pooled RR ~0.31, roughly a 70% reduction) with no increase in miscarriage or other adverse events.
Meta-analysis of RCTs
~12 RCTs, dose-response
✓ PubMed
Folic acid supplements lowered plasma homocysteine by about 25% (~3 µmol/L net reduction), with doses >=0.8 mg/day achieving near-maximal effect and combined vitamin B12 adding ~7% further reduction.
Meta-analysis of RCTs
13 trials / ~50,000 individuals
✓ Full text
In the B-Vitamin Treatment Trialists' meta-analysis, folic acid supplementation (median ~5 years) did not significantly increase overall or site-specific cancer incidence, including colorectal cancer (RR ~1.00).
Clinical guideline
USPSTF reaffirmation (Grade A)
✓ Source
The US Preventive Services Task Force recommends all persons planning or capable of pregnancy take a daily 0.4-0.8 mg (400-800 mcg) folic acid supplement starting >=1 month before conception to prevent neural tube defects.
RCT
Huo 2015 (CSPPT)
✓ PubMed
Landmark double-blind RCT in 20,702 Chinese hypertensive adults without folate fortification: enalapril plus 0.8 mg folic acid vs enalapril alone reduced first stroke by 21% (2.7% vs 3.4%; HR 0.79, 95% CI 0.68-0.93) and first ischemic stroke (HR 0.76, 95% CI 0.64-0.91) over median 4.5 years.
Review
Tang 2026
✓ PubMed
Genomic, transcriptomic, and molecular predictors of response to neoadjuvant therapy in locally advanced rectal cancer: a narrative review
Systematic evidence review
Evidence report, 3 studies n=990,372
✓ PubMed
The 2023 USPSTF evidence review found consistent observational and trial evidence that folic acid supplementation reduces neural tube defect risk, with no convincing evidence of supplementation-related harms at recommended doses.
Review
Nutrients 2024 (Folic Acid vs 5-MTHF Review)
✓ Full text
Evidence-based narrative review of folic acid versus 5-methyltetrahydrofolate supplementation for neural tube defect prevention, synthesizing comparative efficacy of the two folate forms.